Compare · NMTC vs WST
NMTC vs WST
Side-by-side comparison of NeuroOne Medical Technologies Corporation (NMTC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NMTC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.19B, about 1415.7x NMTC ($16.4M).
- Over the past year, NMTC is down 63.9% and WST is up 24.6% - WST leads by 88.5 points.
- WST has been more active in the news (8 items in the past 4 weeks vs 3 for NMTC).
- WST has more recent analyst coverage (18 ratings vs 4 for NMTC).
- Company
- NeuroOne Medical Technologies Corporation
- West Pharmaceutical Services Inc.
- Price
- $1.94+3.74%
- $328.35-7.74%
- Market cap
- $16.4M
- $23.19B
- 1M return
- -41.21%
- -3.45%
- 1Y return
- -63.92%
- +24.62%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 4
- 18
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NMTC
- Amendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies Corporation
- New insider Pratt Brian claimed ownership of 1,085,934 shares (SEC Form 3)
- Market Development Director Christianson Mark sold $31,773 worth of shares (10,000 units at $3.18), decreasing direct ownership by 33% to 20,692 units (SEC Form 4)
- SEC Form 424B5 filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Amendment: SEC Form 10-Q/A filed by NeuroOne Medical Technologies Corporation
- SEC Form SD filed by NeuroOne Medical Technologies Corporation
- SEC Form SD filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target